Abzena PLC Blocklisting update (6509T)
09 January 2017 - 8:37PM
UK Regulatory
TIDMABZA
RNS Number : 6509T
Abzena PLC
09 January 2017
Abzena plc
Block Listing Update
Cambridge, UK, 9 January 2017 - Further to the announcement by
Abzena plc (AIM: ABZA, 'Abzena' or the 'Group') on 6 July 2016, the
Group announces that a total of 75,000 ordinary shares of GBP0.002
each in the share capital of the Group ('Ordinary Shares') have
been issued since that date pursuant to the Group's 2013 Share
Incentive Plan and admitted to trading in accordance with the block
listing applied for on 7 July 2015 (the 'Block Listing'). An update
in accordance with Schedule 6 of the AIM Rules for Companies is set
out below.
The Group holds no shares in treasury and hence the total number
of current voting rights is 137,130,555. The Group will notify on a
monthly basis when there are changes to the issued share capital,
and these monthly figures may be used by shareholders as the
denominator for the calculation by which they will determine if
they are required to notify their interest in, or a change in their
interest in, the share capital of the Group.
BLOCK LISTING SIX MONTHLY RETURN
Name of applicant: Abzena plc
---------------------------------------------------- ----------------------------------------------------------------
Name of scheme: Abzena plc 2013 Share Incentive Plan
---------------------------------------------------- ----------------------------------------------------------------
Period of return: From: 6 July 2016 To: 6 January 2017
-------------------------- ------------------------ -------------------------- --------- -------------------------
Balance of unallotted securities under scheme(s)
from previous return: 832,476
---------------------------------------------------- ----------------------------------------------------------------
Plus: The amount by which the block scheme(s) has Nil
been increased since the date of the last
return (if any increase has been applied for):
---------------------------------------------------- ----------------------------------------------------------------
Less: Number of securities issued/allotted under
scheme(s) during period (see LR3.5.7G): 75,000
---------------------------------------------------- ----------------------------------------------------------------
Equals: Balance under scheme(s) not yet
issued/allotted at end of period 757,476
---------------------------------------------------- ----------------------------------------------------------------
Number and class of securities originally admitted 1,779,000 ordinary shares of GBP0.002 each, admitted on 13 July
and the date of admission 2015
---------------------------------------------------- ----------------------------------------------------------------
Name of contact: Julian Smith
---------------------------------------------------- ----------------------------------------------------------------
Telephone number of contact: +44 1223 903 498
---------------------------------------------------- ----------------------------------------------------------------
Enquiries:
Abzena plc
John Burt, Chief Executive
Officer Julian Smith, Chief
Financial Officer +44 1223 903498
Numis (Nominated Adviser and
Broker)
Clare Terlouw / James Black +44 20 7260
/ Paul Gillam 1000
N+1 Singer (Joint Broker) +44 20 7496
Aubrey Powell / Liz Yong 3000
Instinctif Partners +44 20 7457
Melanie Toyne Sewell / Rozi 2020
Morris abzena@instinctif.com
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products, a growing area that requires specialist
knowledge and expertise. The Group has a global customer base which
includes the majority of the top 20 biopharmaceutical companies as
well as large and small biotech companies and academic groups.
The term "Abzena inside" is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on "Abzena inside" products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA).
-- Immunogenicity assessment, protein engineering to create
humanized antibodies and deimmunised therapeutic proteins, and cell
line development for manufacture.
-- Contract process development and manufacture of
biopharmaceuticals, including monoclonal antibodies, recombinant
proteins, vaccines, and gene therapy and cell therapy products, for
preclinical and clinical studies.
-- Proprietary site-specific conjugation technologies for
antibody drug conjugate development and solutions for optimizing
the therapeutic properties of biopharmaceuticals.
-- Contract chemistry and bioconjugation business focused on
ADCs and is establishing the capability to manufacture ADCs to GMP
standards.
For more information, please see www.abzena.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLREANFNEDKXEEF
(END) Dow Jones Newswires
January 09, 2017 04:37 ET (09:37 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024